ADVISORY, May 7, 2007 (PRIME NEWSWIRE) --
What: John Risner, President of the Children's Tumor Foundation, will preside over the closing bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Tuesday, May 8, 2007 at 4 p.m. ET Contacts: John Risner 212.344.6633 x249; jrisner@ctf.org NASDAQ MarketSite: Jolene Libretto; 646.441.5220; 347.219.9539 Jolene.Libretto@NASDAQ.com
Feed Information:
The closing bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.
Radio Feed:
An audio transmission of the closing bell is also available from 3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Waterfront fiber 1623 as well.
Webcast:
A live Webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm
Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About the Children's Tumor Foundation:
Founded in 1978, The Children's Tumor Foundation is dedicated to improving the health and well being of more than 100,000 Americans living with neurofibromatosis (NF). Our research program has played a key role in the discovery of the genes that cause NF, understanding the biology of NF, creation of The NF Clinic Network and preclinical screening of promising drug compounds to treat the disorder.
NF is a genetic disorder that causes tumors to grow on nerve endings throughout the body. Occurring in 1-3,000 births, NF is more prevalent than cystic fibrosis, Huntington's disease and Duchenne muscular dystrophy combined. Ranging in severity, NF can lead to loss of vision and hearing, disfigurement, skeletal defects, learning disabilities and various forms of cancer, including juvenile leukemia.